Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa

English version České info

Background:
Randomized clinical trials of oral antiretroviral pre-exposure prophylaxis (PrEP) for HIV prevention have widely divergent efficacy estimates, ranging from 0% to 75%. These discrepancies are likely due to differences in adherence. To our knowledge, no studies to date have examined the impact of improving adherence through monitoring and/or intervention, which may increase PrEP efficacy, or reported on objective behavioral measures of adherence, which can inform PrEP effectiveness and implementation.

Methods and Findings:
Within the Partners PrEP Study (a randomized placebo-controlled trial of oral tenofovir and emtricitabine/tenofovir among HIV-uninfected members of serodiscordant couples in Kenya and Uganda), we collected objective measures of PrEP adherence using unannounced home-based pill counts and electronic pill bottle monitoring. Participants received individual and couples-based adherence counseling at PrEP initiation and throughout the study; counseling was intensified if unannounced pill count adherence fell to <80%. Participants were followed monthly to provide study medication, adherence counseling, and HIV testing. A total of 1,147 HIV-uninfected participants were enrolled: 53% were male, median age was 34 years, and median partnership duration was 8.5 years. Fourteen HIV infections occurred among adherence study participants—all of whom were assigned to placebo (PrEP efficacy = 100%, 95% confidence interval 83.7%–100%, p<0.001). Median adherence was 99.1% (interquartile range [IQR] 96.9%–100%) by unannounced pill counts and 97.2% (90.6%–100%) by electronic monitoring over 807 person-years. Report of no sex or sex with another person besides the study partner, younger age, and heavy alcohol use were associated with <80% adherence; the first 6 months of PrEP use and polygamous marriage were associated with >80% adherence. Study limitations include potential shortcomings of the adherence measures and use of a convenience sample within the substudy cohort.

Conclusions:
The high PrEP adherence achieved in the setting of active adherence monitoring and counseling support was associated with a high degree of protection from HIV acquisition by the HIV-uninfected partner in heterosexual serodiscordant couples. Low PrEP adherence was associated with sexual behavior, alcohol use, younger age, and length of PrEP use.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLoS Med 10(9): e32767. doi:10.1371/journal.pmed.1001511
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001511

Souhrn

Zdroje

1. UNAIDS/WHO (2010) AIDS epidemic update. Available: http://www.unaids.org/globalreport. Accessed: 15 October 2012.

2. PadianNS, McCoySI, KarimSS, HasenN, KimJ, et al. (2011) HIV prevention transformed: the new prevention research agenda. Lancet 378: 269–278.

3. BaetenJ, DonnellD, NdaseP, MugoNR, CampbellJD, et al. (2012) Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 367: 399–410.

4. GrantRM, LamaJR, AndersonPL, McMahanV, LiuAY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587–2599.

5. ThigpenMC, KebaabetswePM, PaxtonLA, SmithDK, RoseCE, et al. (2012) Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 367: 423–434.

6. Microbicide Trials Network (MTN) (2011) Statement on decision to discontinue use of oral tenofovir tablets in VOICE, a major HIV prevention study in women. Available: http://www.mtnstopshiv.org/node/3619. Accessed 15 October 2012.

7. Van DammeL, CorneliA, AhmedK, AgotK, LombaardJ, et al. (2012) Preexposure prophylaxis for HIV infection among African women. N Engl J Med 367: 411–422.

8. WilliamsA, FriedlandG (1997) Adherence, compliance, and HAART. AIDS Clin Care 9: 51–58, 51-54, 58.

9. KashubaADM, PattersonKB, DumondJB, CohenMS (2012) Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet 6736: 61852–61857.

10. van der StratenA, Van DammeL, HabererJE, BangsbergDR (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13–F19.

11. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, et al. (2013) Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine, or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; Atlanta, 3–6 March 2013; paper number 26LB.

12. AndersonPL, GliddenDV, LiuA, BuchbinderS, LamaJR, et al. (2012) Emtricitabine- tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med 4: 151ra25.

13. PodsadeckiTJ, VrijensBC, ToussetEP, RodeRA, HannaGJ (2008) “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 9: 238–246.

14. SimoniJM, KurthAE, PearsonCR, PantaloneDW, MerrillJO, et al. (2006) Self-report measures of antiretroviral therapy adherence: A review with recommendations for HIV research and clinical management. AIDS Behav 10: 227–245.

15. HugenPW, LangebeekN, BurgerDM, ZomerB, van LeusenR, et al. (2002) Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. J Acquir Immune Defic Syndr 30: 324–334.

16. LiechtyCA, AlexanderCS, HarriganPR, GuzmanJD, CharleboisED, et al. (2004) Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS 18: 127–129.

17. BangsbergDR, HechtFM, CharleboisED, ZolopaAR, HolodniyM, et al. (2000) Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 14: 357–366.

18. OyugiJH, Byakika-TusiimeJ, CharleboisED, KityoC, MugerwaR, et al. (2004) Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr 36: 1100–1102.

19. Psaros C (2011) An adherence intervention to support HIV pre-exposure prophylaxis (PrEP) adherence in serodiscordant couples in Uganda. 6th Annual International Conference on HIV Treatment and Prevention Adherence; Miami, 22–24 May 22–24; number 70065.

20. Garcia-LermaJG, OttenRA, QariSH, JacksonE, CongME, et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28 doi:10.1371/journal.pmed.0050028

21. Abdool KarimQ, Abdool KarimSS, FrohlichJA, GroblerAC, BaxterC, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168–1174.

22. FilmerD, PritchettLH (2001) Estimating wealth effects without expenditure data—or tears: an application to educational enrollments in states of India. Demography 38: 115–132.

23. CherpitelCJ, YeY, BondJ, BorgesG, CremonteM, et al. (2005) Cross-national performance of the RAPS4/RAPS4-QF for tolerance and heavy drinking: data from 13 countries. J Stud Alcohol 66: 428–432.

24. BoltonP, WilkCM, NdogoniL (2004) Assessment of depression prevalence in rural Uganda using symptom and function criteria. Soc Psychiatry Psychiatr Epidemiol 39: 442–447.

25. WeissHA, WasserheitJN, BarnabasRV, HayesRJ, Abu-RaddadLJ (2008) Persisting with prevention: the importance of adherence for HIV prevention. Emerg Themes Epidemiol 5: 8.

26. HahnJA, Woolf-KingSE, MuyindikeW (2011) Adding fuel to the fire: alcohol's effect on the HIV epidemic in Sub-Saharan Africa. Curr HIV/AIDS Rep 8: 172–180.

27. SmithRM, CarricoAW, MontandonM, KwenaZ, BaileyR, et al. (2011) Attitudes and beliefs about anti-retroviral therapy are associated with high risk sexual behaviors among the general population of Kisumu, Kenya. AIDS Care 23: 1668–1675.

28. PittmanME, SecuraGM, AllsworthJE, HomcoJB, MaddenT, et al. (2011) Understanding prescription adherence: pharmacy claims data from the Contraceptive CHOICE Project. Contraception 83: 340–345.

29. WareNC, WyattMA, HabererJE, BaetenJM, KintuA, et al. (2012) What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 59: 463–468.

30. EyawoO, de WalqueD, FordN, GakiiG, LesterRT, et al. (2010) HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis 10: 770–777.

31. UNAIDS (2010) Getting to zero: 2011–2015 strategy. Available: https://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2010/JC2034_UNAIDS_Strategy_en.pdf. Accessed 28 January 2013.

32. BangsbergDR, HechtFM, CharleboisED, ChesneyM, MossA (2001) Comparing Objective measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 5: 275–281.

33. SafrenSA, KumarasamyN, HosseinipourM, HarwoodMM, HoffmanI, et al. (2006) Perceptions about the acceptability of assessments of HIV medication adherence in Lilongwe, Malawi and Chennai, India. AIDS Behav 10: 443–450.

34. HabererJE, KahaneJ, KigoziI, EmenyonuN, HuntP, et al. (2010) Real-time adherence monitoring for HIV antiretroviral therapy. AIDS Behav 14: 1340–1346.